Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|September 27, 2013

Coldstream Laboratories for Parental Dosage Forms NCI Contract

Coldstream Laboratories partners with the National Cancer Institute for developing parental dosage forms for cancer drugs.

Coldstream Laboratories, a provider of sterile drug-product development and manufacturing services, has been awarded a five-year contract with the National Cancer Institute (NCI), with the objective of developing and producing pharmaceutically acceptable parenteral dosage forms of cancer drugs for human use. Certain lead agents selected by the NCI will be assigned for development and production as parenteral products.

Coldstream Laboratories, based in Lexington, Kentucky, is a privately held CMO. It was formed in 2007 as a spin off from the University of Kentucky's Center for Pharmaceutical Sciences and Technology.


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.